Abstract | BACKGROUND: METHODS: Using Cochrane methodology, we reviewed all randomised placebo controlled trials of IFNβ in SPMS patients (1995-March 2012). RESULTS: 5 trials (3082 patients) were included. After 3 years, interferons did not reduce disability progression, confirmed at 6 months (RR 0.98, 95% CI 0.82 to 1.16). A small reduction in the number of patients who had relapses during the first 3 years of treatment (RR 0.91, 0.84 to 0.97) was found. No analysis of cognitive data was possible. More treated than placebo patients dropped out for adverse events. CONCLUSION: 3 year treatment with IFNβ does not delay permanent disability in SPMS but reduces relapse risk, indicating that the anti-inflammatory effect of IFNβ is unable to prevent MS progression once it has become established.
|
Authors | Loredana La Mantia, Laura Vacchi, Marco Rovaris, Carlo Di Pietrantonj, George Ebers, Sten Fredrikson, Graziella Filippini |
Journal | Journal of neurology, neurosurgery, and psychiatry
(J Neurol Neurosurg Psychiatry)
Vol. 84
Issue 4
Pg. 420-6
(Apr 2013)
ISSN: 1468-330X [Electronic] England |
PMID | 22952326
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Chemical References |
- Immunologic Factors
- Recombinant Proteins
- Interferon beta-1b
- Interferon-beta
- Interferon beta-1a
|
Topics |
- Adolescent
- Adult
- Age Factors
- Aged
- Disability Evaluation
- Disease Progression
- Female
- Follow-Up Studies
- Humans
- Immunologic Factors
(adverse effects, therapeutic use)
- Interferon beta-1a
- Interferon beta-1b
- Interferon-beta
(adverse effects, therapeutic use)
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Multiple Sclerosis, Chronic Progressive
(drug therapy, pathology, psychology)
- Publication Bias
- Quality of Life
- Randomized Controlled Trials as Topic
- Recombinant Proteins
(therapeutic use)
- Recurrence
- Treatment Outcome
- Young Adult
|